Treatment Trials in Young Patients with Chronic Obstructive Pulmonary Disease and Pre–Chronic Obstructive Pulmonary Disease Patients: Time to Move Forward

Chronic obstructive pulmonary disease (COPD) is the end result of a series of dynamic and cumulative gene–environment interactions over a lifetime. The evolving understanding of COPD biology provides novel opportunities for prevention, early diagnosis, and intervention. To advance these concepts, we propose therapeutic trials in two major groups of subjects: “young” individuals with COPD and those with pre-COPD. Given that lungs grow to about 20 years of age and begin to age at approximately 50 years, we consider “young” patients with COPD those patients in the age range of 20–50 years. Pre-COPD relates to individuals of any age who have respiratory symptoms with or without structural and/or functional abnormalities, in the absence of airflow limitation, and who may develop persistent airflow limitation over time.
Puedes leer el artículo completo aquí: https://www.atsjournals.org/doi/full/10.1164/rccm.202107-1663SO
Autores: Fernando J. Martinez, Alvar Agusti, Bartolome R. Celli, MeiLan K. Han, James P. Allinson, Surya P. Bhatt, Peter Calverley, Sanjay H. Chotirmall, Badrul Chowdhury, Patrick Darken, Carla A. Da Silva, Gavin Donaldson, Paul Dorinsky, Mark Dransfield, Rosa Faner, David M. Halpin, Paul Jones, Jerry A. Krishnan, Nicholas Locantore, Fernando D. Martinez, Hana Mullerova, David Price, Klaus F. Rabe, Colin Reisner, Dave Singh, Jørgen Vestbo, Claus F. Vogelmeier, Robert A. Wise, Ruth Tal-Singer, and Jadwiga A. Wedzicha.
Noticias relacionadas

Clinical characteristics of chronic obstructive pulmonary disease in never-smokers: A systematic review
Chronic Obstructive Pulmonary Disease (COPD) is the third cause of death worldwide. While tobacco smoking is a key risk factor, COPD also occurs in never-smokers (NS).

XXXV Jornadas Técnicas del Institut Guttmann
El 21 de junio se celebrará en CaixaFòrum Barcelona las XXXV Jornadas Técnicas del Institut Guttmann. Este año las jornadas están dedicadas a la humanización en la asistencia, con el foco en la neurorrehabilitación

ERJ Podcast: GOLD 2023
Chief Editor James Chalmers interviews Alvar Agusti (Hospital Clinic, Barcelona, Spain)about the new Global Initiative for Chronic Obstructive Lung Disease (GOLD) report. Listen it here.
Más artículos
COPD
- 769799·Alvar Agusti, Peter G. Gibson, Vanessa M. McDonald. Treatable Traits in Airway Disease: From Theory to Practice
- 769874·Bartolome R Celli et Al. Differential Diagnosis of Suspected COPD Exacerbations in the Acute Care Setting: Best Practice
- 778791·Alvar Agusti et Al. COPD: Providing the right treatment for the right patient at the right time
- 778987·Àlvar Agustí et al. Lifetime spirometry patterns of obstruction and restriction, and their risk factors and outcomes: a prospective cohort study
- 779376·Gerard J. Criner, Alvar Agusti, Hossein Borghaei, Joseph Friedberg, Fernando J. Martinez, Curtis Miyamoto, Claus F. Vogelmeier, Bartolome R. Celli.Chronic Obstructive Pulmonary Disease and Lung Cancer: A Review for Clinicians
Recuerda que puedes acceder a varios enlaces a artículos dentro de la categoría EPOC en esta web. También puedes acceder otros enlaces en el Listado de Artículos de la Cátedra de Salud Respiratoria.
Imagen obtenida en el artículo original.